157 related articles for article (PubMed ID: 36412315)
1. Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report.
Dalvi RC; Mandava S; Pais AP; Kokate PP; Sinha N; Nath UK
Indian J Cancer; 2022; 59(3):419-421. PubMed ID: 36412315
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
3. A short report of novel
Song Y; Hou J; Wan L; Liu K; Zhou C; Wei S; Zhang G; Lin D; Li Y; Fang Q; Liu Y; Gong B; Gong X; Wang Y; Wei H; Wang J; Mi Y
Hematology; 2022 Dec; 27(1):518-522. PubMed ID: 35544458
[TBL] [Abstract][Full Text] [Related]
4. Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases.
Liu G; Liu L; Bartolo DD; Li KY; Li X
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672788
[TBL] [Abstract][Full Text] [Related]
5. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
8. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
Lauricella C; Greco R; Mancini V; Motta V; Ciraolo A; De Canal G; De Paoli E; Paglino G; Guido V; Bonoldi E; Veronese S; Soriani S
Acta Haematol; 2023; 146(1):58-64. PubMed ID: 36198282
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
He Y; Li X; Wang D; Zhang E; Hu Y; Wang W; Huang R; Xiao R
J Int Med Res; 2014 Dec; 42(6):1363-73. PubMed ID: 25223426
[TBL] [Abstract][Full Text] [Related]
11. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Calleja EM; Warrell RP
Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
13. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
14. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
[TBL] [Abstract][Full Text] [Related]
16. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
[TBL] [Abstract][Full Text] [Related]
17. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
18. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
19. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Ramos Perez JM; Patel KP; Loghavi S; Garcia-Manero G; Borthakur G; Jabbour E; Wierda W; Pierce S; Brandt M; Kornblau S; Kadia T; Daver N; DiNardo CD; Jain N; Yilmaz M; Short N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Rivera D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2022 Mar; 63(3):672-675. PubMed ID: 34668451
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
